Orlando, FL -- (SBWIRE) -- 09/04/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Key Energy Services, Inc. (NYSE:KEG), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR).
Key Energy Services, Inc. (NYSE:KEG) shares increased 6% to $7.07. Barclays analyst James C. West upgraded the shares to "Overweight," from "Equal Weight." He raised his price target to $10 from $7. Separately, Equities researchers at Howard Weil dropped their price target on shares of KEG from $11.00 to $10.00 in a research report issued on August 29. The firm currently has a “sector perform” rating on the stock.
Additionally, the company issued its quarterly earnings data on July 25. The company reported $0.01 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.01. The company had revenue of $411.40 million for the quarter, compared to the consensus estimate of $421.24 million.
Are investors worried about the recent updates with KEG? Find out with a free trend analysis HERE
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares gained 5.59% to $5.39. The company on Sept 3 announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules. The settlement agreement grants Actavis the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.
Additionally, the company on August 22 announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States.
Moreover, the company on August 12 said it reached an exclusive agreement to promote pharmaceutical giant Merck & Co.'s type-2 diabetes drug Januvia in long-term care institutional settings in the U.S. Under the accord, Avanir institutional sales force will begin promoting the sitagliptin family of products to health-care practitioners in the long-term care institutional setting in October.
Is AVNR going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)